What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?-Reference-Cited by-同舟云学术

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

Published:2023-07-21 Issue: Volume: Page:
ISSN:1522-8517
Container-title:Neuro-Oncology
language:en
Short-container-title:

Author:

Preusser Matthias¹^ORCID,Geurts Marjolein²,Hainfellner Johannes A³,van den Bent Martin J²

Affiliation:

1. Division of Oncology, Department of Medicine 1, Medical University , Vienna , Austria

2. The Brain Tumour Center at the Erasmus MC Cancer Institute , Rotterdam , The Netherlands

3. Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna , Vienna , Austria

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Neurology (clinical),Oncology

Link

https://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noad113/50926104/noad113.pdf

Reference14 articles.

1. The 2021 WHO classification of tumors of the central nervous system: A summary;Louis;Neuro Oncol,2021

2. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline;Sahm;Neuro Oncol,2023

3. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma;Mellinghoff;N Engl J Med.,2023

4. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: A clinician’s perspective;van den Bent;Acta Neuropathol.,2010

5. Grading of diffuse astrocytic gliomas: A review of studies before and after the advent of IDH Testing;von Deimling;Semin Neurol.,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular imaging of IDH-mutant gliomas in the new era of IDH inhibitors: preparing for future challenges;European Journal of Nuclear Medicine and Molecular Imaging;2024-01-09